



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Monday, November 09, 2009

## ThromboTargets Corporation

[View the current ThromboTargets Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/31064-ThromboTargets+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/31064-ThromboTargets+Corporation.html>)

### Contact Details:

**2530 Meridian Parkway, Suite 3024  
Durham  
North Carolina  
27713  
United States of America**

Tel: +1 919 806 4254  
Fax: +1 919 806 4870  
Email: [info@thrombotargets.com](mailto:info@thrombotargets.com)

Thrombotargets Corporation is an innovative US Biotech Company based on Drug Discovery and Development of new medicines focused on advances in recombinant DNA and small molecules. Thrombotargets's programs leverage the company's hemostasis expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic disorders. Furthermore, Thrombotargets is developing projects in other interesting therapeutical areas as as Atherotrombotic, Cancer, Neurodegenerative and Ageing related disorders.

Thrombotargets is integrated by Thrombotargets Corporation (Durham, NC, USA.) is responsible for Drug Development and Business Management; Thrombotargets Europe (Barcelona, Spain) projected for Target Identification, Lead Validation, Lead Optimization and Biotech Libraries (Spain) for engineered targeted libraries and High Throughput Screening (HTS – PA) Services.

With a primary focus on therapeutics for Hemostasis and Thrombotic diseases, Thrombotargets's objective is to identify, optimize and develop highly efficacious biotech small molecule leads to cover the current market needs.

Thrombotargets will achieve their objectives by operating a balanced risk business strategy: 1. Invest in our own discovery and development programs and drive these through to clinical phases before partnering the candidate with pharmaceutical companies. 2. Collaborate with the pharmaceutical industry leaders to share the investment and the rewards associated with generating market outcomes for innovative new therapies through the commercialization of BioPlatformScreen™ 3. Through the in-licensing of programs at stages of development that complement and balance our existing internal portfolio, Thombotargets leverage external innovation .

### Proprietary Technology

**Thrombotargets has developed and adapted to High Throughput Screening (HTS), a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (Hemosta-BioPlatformScreen), total antioxidant capacity (Oxidant-BioPlatformScreen) and low-density lipoprotein modification (Athero-BioPlatformScreen). With these proven proprietary HTS Platforms named BioPlatformScreen™, the Thrombotargets is creating a continuously novel and promising pipeline. Presently, two of Thrombotargets most innovative drug candidates, TT-103MH, a novel antihemorrhagic human recombinant protein to be use topically, and TT-105, a novel**

anticoagulant monoclonal antibody, are undergoing Preclinical trials; these programs will begin Phase I clinical trials Q4, 2007. Furthermore we have begun a new antifibrinolytic program (TT-111 and TT-112) in collaboration with ASINEX, Russia due to results in the exploitation of our BioplatfromScreen™ Technology. Recently, two new Anti-coagulant (TT-123 and TT-124) found out through libraries of small molecules in association with Specs, Delft (Netherlands).

**Download Detailed Profile** Full corporate profile including details on recent and anticipated activities, current alliances, intellectual property status, products, financing strategy and investors. Also details on senior management, board of directors and scientific advisory board can be viewed: [Download Corporate Information PDF](#)

## Press Releases listed on BioPortfolio

- [Thrombotargets Corporation and Dr. Cam Patterson, Director of the Carolina Cardiovascular Biology Center at the University of North Carolina to create a Joint Venture for the exploitation of their proprietary technologies.](#)
- [Thrombotargets Corporation announces the incorporation of Steven Hite as a Chief Operating Officer based in North Carolina, USA.](#)
- [Thrombotargets Corp. and Magellan Bioscience Group, Inc. to collaborate on identification of novel hits from both marine derivate and natural products.](#)
- [Thrombotargets Corp announced today that it has submitted its Orphan Drug Application of TT-103MH to the FDA for bleeding treatment in von Willebrand patients](#)
- 
- 
- 
- 
- 
- 
- 

Corporate Web Site Content [Home](#) | [Corporate](#) | [Pipeline](#) | [Discovery and Development](#) | [Partnering](#) | [Investors](#) | [News](#) | [Contact](#) .

### Press Releases on ThromboTargets Corporation:

<a href="#">Centene Corporation to Present at Upcoming Healthcare Conferences</a>	6th November, 2009 Centene Corporation	ST. LOUIS, Nov. 6 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at two upcoming healthcare conferences over the next few weeks. Next week, at the
-----------------------------------------------------------------------------------	----------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Reissue with Tables:  
BioSpecifics Technologies  
Corp. Reports Third  
Quarter 2009 Financial  
Results](#)

6th November, 2009 BioSpecifics  
Technologies Corp.

-- In its September 3, 2009  
edition, *The New England  
Journal of Medicine* published  
data from the pivotal *CORD I  
Phase III clinical trial of XIAFLEX  
for the treatment of Dupuytren*

["AIM"ING FOR BETTER  
ASTHMA CARE](#)

6th November, 2009 Schering Corporation

*Asthma Insight and  
Management (AIM) Survey  
Reveals Unmet Needs in  
Current Asthma Care in the  
United States Asthma is a  
chronic condition affecting more  
than 22 million adults and  
children in*

[Caraco Pharmaceutical  
Laboratories, Ltd. Markets  
Generic Acular\(R\)  
Ophthalmic Solution](#)

6th November, 2009 Caraco Pharmaceutical  
Laboratories, Ltd.

*DETROIT, Nov. 6  
/PRNewswire-FirstCall/ --  
Caraco Pharmaceutical  
Laboratories, Ltd. (NYSE Amex:  
CPD) has launched ketorolac  
tromethamine ophthalmic  
solution, 0.5% following a final  
approval from the US*

[Myriant Technologies  
LLC, Uhde Corporation of  
America and Uhde GmbH  
Announce Alliance for  
Engineering, Procurement  
& Construction of World  
Scale Renewable  
Succinic Acid Plants](#)

6th November, 2009 Myriant Technologies  
LLC

*QUINCY, Mass., Nov. 6  
/PRNewswire/ -- Myriant  
Technologies LLC ("Myriant"), a  
privately-held, biotech developer  
and manufacturer of renewable  
bio-chemicals, Uhde Corporation  
of America and*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

[Thrombotargets Corporation Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Procoagulant Agent, TT-103MH, in the Treatment of Bleeding Episodes in Hemophiliacs](#)

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search

- engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

